Last updated: 07/17/2024 15:34:55
Lamotrigine Phase III study in bipolar I disorder
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Fixed-Dose Study of Lamotrigine versus Placebo in the Long Term Prevention of Relapse and/or Recurrence of a Manic, Hypomanic, Mixed or Depressive Episode in Adult Subjects with Bipolar I Disorder
Trial description: This registration study in China is a multi-centre, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of lamotrigine in the prevention of recurrence/relapse of mood episodes in subjects with bipolar I disorder. Subjects are bipolar I disorder patients with recent/current manic, hypomanic, mixed or depressive episode. The study will include an open-label phase and a randomized phase. During the open-label phase, subjects will have lamotrigine monotherapy or combination therapy escalation. The target dose of lamotrigine is 200 milligram (mg)/day monotherapy. The duration of treatment in the open-label phase will last 6-16 weeks, until subjects reach a stable dose of lamotrigine. Beginning at week 7 of the open-label phase, subjects who have reached a stable dose of lamotrigine and met response criteria, defined as maintaining a Clinical Global Impression of Severity (CGI-S) score <= 3 for at least 4 continuous weeks and maintaining lamotrigine 200 mg/day monotherapy for at least 1 week, will be eligible to enroll in the double-blind phase of the study. Subjects who have not met response criteria after 16 weeks of participation in the open-label phase will be withdrawn from the study. Subjects will have lamotrigine 200 mg/day monotherapy for at least 1 week prior to randomization. Subjects who have met randomization requirements will be randomized 1:1 to lamotrigine 200 mg/day or placebo for 36 weeks double-blind treatment. After randomization, subjects will be assessed at weekly intervals for the first month, biweekly intervals for the second month, and then at monthly intervals for up to 36 weeks of double-blind treatment. The primary endpoint will be TIME, defined as the time to intervention (addition of pharmacotherapy or electroconvulsive therapy [ECT]) for any mood episode (relapse or recurrence of a depressive, manic, hypomanic or mixed episode) after randomization. The secondary endpoints will include time to intervention for manic, hypomanic or mixed episode (TIMan) and time to intervention for depressive episode (TIDep).The scores on the Hamilton Depression (HAMD), Young Mania Rating Scale (YMRS), CGI-I, CGI-S and Global Assessment Scale (GAS) will be used as indicators for both intensity and duration of mood symptoms during this phase. Subjects who withdraw early from the study prior to week 36 or reach TIME will have a follow-up visit 14 days after the last dose of investigational drug.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Time to intervention for any mood episode (TIME)
Timeframe: 36 weeks (wks)
Secondary outcomes:
Time to Intervention for Manic, Hypomanic or Mixed Episode (TIMan)
Timeframe: 36 weeks
Time to intervention for depressive episode (TIDep)
Timeframe: 36 weeks
Overall survival in study (TIME-SIS).
Timeframe: 36 weeks
Change from baseline in Clinical Global Impression of Improvements (CGI-I)
Timeframe: Baseline and up to 36 weeks
Change from baseline in Clinical Global Impression of Severity (CGI-S)
Timeframe: Baseline and up to 36 weeks
Change from baseline in Hamilton Depression Rating Scale (HAMD)
Timeframe: Baseline and up to 36 weeks
Change from baseline in Young Mania Rating Scale (YMRS) total score
Timeframe: Baseline and up to 36 weeks
Change from baseline of Global Assessment Scale (GAS) total score
Timeframe: Baseline and up to 36 weeks
Change from baseline in body weight
Timeframe: Baseline and up to 36 weeks.
Interventions:
Enrollment:
265
Primary completion date:
2015-01-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Daniel W. Coyne, Ajay K. Singh, Renato D. Lopes, Christine K. Bailey, Tara L. DiMino, Chun Huang, Jeffrey Connaire, Anjay Rastogi, Sung-Gyun Kim, Marcelo Orias, Sapna Shah, Vickas Patel, Alexander R. Cobitz, Christoph Wanner. Three-Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. Clin J Am Soc Nephrol. 2022;
DOI: https://doi.org/10.2215/CJN.00550122
PMID: NULL
Ling Zhang, Honggeng Zhang, Lu-xian Lv, Qingrong Tan, Xiufeng Xu, Jian Hu, Lu Zi, Gang Wang, James Cooper, Abhay Phansalkar.A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lamotrigine in the maintenance treatment of Chinese adult patients with bipolar I disorder.Int J Bipolar Disord.2022;10(1):20
DOI: https://doi.org/10.1186/s40345-022-00266-4
PMID: 35909213
Medical condition
Bipolar Disorder
Product
lamotrigine
Collaborators
Not applicable
Study date(s)
August 2012 to December 2015
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- For open label phase
- Subjects must be able to effectively communicate with study personnel, have the ability to comprehend the key components of the Inform Consent Form and must provide written informed consent to participate in the study prior to any study-specific assessments or procedures.
- For open label
- Has met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for rapid cycling and has had more than 4 manic, hypomanic, mixed or depressive episodes in the 12-month period prior to enrollment.
Inclusion and exclusion criteria
Inclusion criteria:
- For open label phase
- Subjects must be able to effectively communicate with study personnel, have the ability to comprehend the key components of the Inform Consent Form and must provide written informed consent to participate in the study prior to any study-specific assessments or procedures.
- An in-patient or out-patient (male or female) and aged >=18 years old.
- Disease to be studied: Has a diagnosis of the following disease as defined by DSM-IV criteria currently or within 60 days: a)Bipolar I Disorder, most recent episode depressed (296.5x); b)Bipolar I Disorder, most recent episode hypomanic (296.40); c)Bipolar I Disorder, most recent episode manic (296.4x); d)Bipolar I Disorder, most recent episode mixed (296.6x)
- The subject who has a diagnose of “bipolar I disorder, most recent episode depressed (296.5x)” must meet the following criteria: Has at least one well documented manic, hypomanic or mixed episode, as defined by DSM-IV criteria, within 3 years of enrolment ; The duration of recent/current depressive episode is at least 2 weeks but not longer than 12 months prior to enrolment; For subject with currently experiencing a depressive episode, he/she must have a minimum total score of 18 on the HAMD-17 at s screening.
- The subject who has a diagnosis of “bipolar I disorder, most recent episode hypomanic (296.40)” or “bipolar I disorder, most recent episode manic (296.4x)” or “bipolar I disorder, most recent episode mixed (296.6x)” must meet the following criteria: Has had at least one well documented additional manic, hypomanic or mixed episode and one depressed episode, as defined by DSM-IV criteria, within 3 years of enrolment; Has a duration of the index manic episode of at least 1 week (unless hospitalised) or hypomanic episode of at least 4 days or mixed episode of at least 1 week. In neither case should the index episode be more than 12 months in duration; If the subject’s index episode is the subject’s initial/current manic mood event, subject must have a minimum score of 10 on the first 11 items of the YMRS at screening; If the subject’s index episode is the subject’s initial/current mixed mood event, subject must have a minimum score of 10 on the first 11 items of the YMRS, and have a minimum score of 18 on the HAMD-17 at screening. For randomized double-blind phase
- Has been on Lamotrigine 200 mg/day monotherapy for at least 1 week.
- CGI-S score <= 3 for at least 4 continuous weeks of treatment prior to randomization.
- Has demonstrated adequate compliance with IP (compliance rate: 75%-125%, inclusive).
Exclusion criteria:
- For open label
- Has met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for rapid cycling and has had more than 4 manic, hypomanic, mixed or depressive episodes in the 12-month period prior to enrollment.
- Has a significant DSM-IV Axis II diagnosis which would suggest non-responsiveness to pharmacotherapy for bipolar disorder or non-compliance with the protocol.
- Has a current or previous diagnosis of an Axis I disorder (including anorexia nervosa or bulimia nervosa) with the exception of bipolar disorder or has received corresponding treatment, or has been diagnosed with dysthymia within the previous 2 years.
- Has signs or symptoms of psychosis.
- The subject, in the investigator’s judgment, poses a suicidal risk, has attempted suicide within 6 months prior to screening (assessed using the Columbia Suicide Severity Rating Scale Baseline) or .
- Has documented Intelligence quotient < 70 or suspected mental retardation.
- Has a history of substance abuse or dependence within 12 months prior to enrolment (DSM-IV defined substance categories, excluding nicotine and caffeine and including alcohol), or has as a positive urine test for illicit drug use (excluding nicotine and caffeine).
- Has received fluoxetine within 4 weeks prior to entry into the open-label phase; has received oral contraceptives or other hormonal preparations containing estrogen within 2 weeks prior to entry into the open-label phase; has received lopinavir/ritonavir or atazanavir /ritonavir within 7 days prior to the baseline visit.
- Has a clinically significant and/or unstable medical disorder (with or without lab test results); or clinically significant test results (thyroid function, electrocardiogram, hematology, clinical chemistry, or urinalysis) as per investigator’s judgment; or a disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of lamotrigine; per investigator’s clinical judgment (after consulting GSK medical monitor), might pose a safety concern; or interfere with the accurate assessment of safety or efficacy.
- Has a history or current diagnosis of epilepsy.
- Is morbidly obese, i.e. if Body Mass Index (BMI) is > 35 {BMI = Body weight (in kg) divided by (Height in meters squared).
- Single or average QT interval corrected by Bazette’s formulaQTcB or QTc > 450 millisecond (msec); for patients with bundle branch block QTc > 480 msec.
- Has a history of hepatic dysfunction; Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >= 2 x upper limit of normal (ULN); Alkaline phosphatase (ALP) or total bilirubin > 1.5 x ULN (excluding total bilirubin > 1.5 x ULN but direct bilirubin < 35%) or other conditions which, in the investigator’s judgment, would render patients unsuitable for the study.
- Has a history of drug allergy (including rash) or a medically significant adverse effect from any ingredient of lamotrigine, or a history of rash due to anti-epileptic drugs or has frequent and/or serious hypersensitivity reaction to multiple drugs.
- Participation in any study related to lamotrigine within 6 months before screening or has received lamotrigine within 4 weeks before screening.
- Participation in another clinical study unrelated to the current illness currently or within the previous 30 days, or 3 months for studies related to the current illness.
- Initiation of systematic psychotherapy within 3 months prior to screening or planned initiation of systematic psychotherapy during the study.
- Female subjects who are pregnant, lactating or do not agree to use the contraceptive methods such as use of condom, injection of progesterone, a reliable barrier method of birth control, partner with vasectomy or abstinence during the study. For randomized double blind phase
- Has signs or symptoms of psychosis.
- Requires treatment for a manic or mixed episode in the open-label phase with new courses of lithium, psychotropic drugs or other drugs with a half-life greater than 14 days.
- Has become actively suicidal and/or has a score >=3 on item 3 of the HAMD.
- Has tested positive for an illicit drug on lab analysis administered before randomization or alcohol abuse/addiction.
- Has had a change in lamotrigine dosage during the last week of the open-label phase.
Trial location(s)
Showing 1 - 6 of 21 Results
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2015-01-12
Actual study completion date
2015-01-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website